Our funding

Rethink Mental Illness aims to raise money from a wide range of fundraising activities to help us maximise the impact of our work with people affected by mental illness. This strategy includes soliciting donations from individuals, charitable trusts and corporate supporters.

As an organisation which fights discrimination and campaigns for better services, our independent voice is crucial. We are clear with all our funders that no donation can challenge this independence in any way, and our corporate partners sign up to a written agreement which states this position.

We believe that dialogue with pharmaceutical companies about any concerns over medications, encouraging the production of better medication and improved medicating and prescribing practice is central to our mission of improving lives.

We therefore accept funding from pharmaceutical companies, on the basis that, as with all our other funders, their gifts support our work without compromising it. Discussions with pharmaceutical companies about medication and treatments will always be unrelated to any funds which we receive from them, and, as a matter of principle, we do not endorse particular drugs or treatments.

Pharmaceutical support represents only a very small portion of our overall funding each year. In line with legal requirements, we publish details of recent pharmaceutical funding on this page of our website.

In 24/25 we received a total of £157,038 from pharmaceuticals these break down as:

• £75,000 from Johnson & Johnson Innovative Medicine
• £15,000 from Teva UK
• £67,038 from Boehringer Ingelheim

In 23/24 we recieved £15,000 from Bristol Meyers Squibbs

If you would like further information about fundraising, please contact our team by sending an email to corporates@rethink.org.